Opsonix is developing and commercializing products based on engineered human opsonin proteins to transform the treatment and diagnosis of bloodstream infections, including sepsis. Opsonins are natural components of the human body’s innate immune system and normally serve to bind infectious invaders, enabling their clearance by phagocytosis while triggering immune responses.
Our most advanced engineered protein, FcMBL, is a recombinant protein derived from human opsonin mannose binding lectin (MBL) fused to the Fc region of human immunoglobulin. MBL naturally binds to the carbohydrate patterns found on the surface of all pathogens classes that induce bloodstream infections and sepsis, including bacteria, viruses, fungi, parasites and toxins, but does not bind to healthy human cells. With Opsonix’s unique opsonin engineering approach, FcMBL retains the normal broad-spectrum pathogen-binding function of natural MBL while avoiding the unwanted immune responses triggered by the natural protein.